Publications

Search ACTG publications from 1/1/2006 to current.

Search

Filter results by

Found 45 results
Filters: First Letter Of Last Name is K  [Clear All Filters]
Found 45 results.
Skip Alphabet Links A  B  C  D  E  F  G  H  I  J  K  L  M  N  O  P  Q  R  S  T  U  V  W  X  Y  Z  

K

Kalayjian RC, Machekano RN, Rizk N, et al. "Pretreatment levels of soluble cellular receptors and interleukin-6 are associated with HIV disease progression in subjects treated with highly active antiretroviral therapy." J. Infect. Dis.. 2010;201(12):1796-805.
Kalayjian RC, Spritzler J, Matining RM, et al. "Older HIV-infected patients on antiretroviral therapy have B-cell expansion and attenuated CD4 cell increases with immune activation reduction." AIDS. 2013;27(10):1563-71.
Kalayjian RC, Wu K, Evans S, et al. "Proteinuria is associated with neurocognitive impairment in antiretroviral therapy treated HIV-infected individuals." J. Acquir. Immune Defic. Syndr.. 2014;67(1):30-5.
Kalayjian RC, Franceschini N, Gupta SK, et al. "Suppression of HIV-1 replication by antiretroviral therapy improves renal function in persons with low CD4 cell counts and chronic kidney disease." AIDS. 2008;22(4):481-7.
Kalayjian RC, Albert JM, Cremers S, et al. "Women have enhanced bone loss associated with phosphaturia and CD4+ cell restoration during initial antiretroviral therapy." AIDS. 2018;32(17):2517-2524.
Kallianpur AR, Gerschenson M, Hulgan T, et al. "Hemochromatosis (HFE) Gene Variants Are Associated with Increased Mitochondrial DNA Levels During HIV-1 Infection and Antiretroviral Therapy." AIDS Res. Hum. Retroviruses. 2018;34(11):942-949.
Kallianpur AR, Hulgan T, Canter JA, et al. "Hemochromatosis (HFE) gene mutations and peripheral neuropathy during antiretroviral therapy." AIDS. 2006;20(11):1503-13.
Kang M, Chung RT. "The role of early viral decline in the treatment of hepatitis C in HIV-1-coinfected persons." J. Acquir. Immune Defic. Syndr.. 2007;46(3):371-3.
Kang M, Cu-Uvin S. "Association of HIV viral load and CD4 cell count with human papillomavirus detection and clearance in HIV-infected women initiating highly active antiretroviral therapy." HIV Med.. 2012;13(6):372-8.
Kang M, Hollabaugh K, Pham V, et al. "Virologic and serologic outcomes of mono versus dual HBV therapy and characterization of HIV/HBV coinfection in a US cohort." J. Acquir. Immune Defic. Syndr.. 2014;66(2):172-80.
Kantor R, Bettendorf D, Bosch RJ, et al. "HIV-1 RNA levels and antiretroviral drug resistance in blood and non-blood compartments from HIV-1-infected men and women enrolled in AIDS clinical trials group study A5077." PLoS ONE. 2014;9(4):e93537.
Kantor R, Smeaton L, Vardhanabhuti S, et al. "Pretreatment HIV Drug Resistance and HIV-1 Subtype C Are Independently Associated With Virologic Failure: Results From the Multinational PEARLS (ACTG A5175) Clinical Trial." Clin. Infect. Dis.. 2015;60(10):1541-9.
Kapadia SN, Wu C, Mayer KH, et al. "No change in health-related quality of life for at-risk U.S. women and men starting HIV pre-exposure prophylaxis (PrEP): Findings from HPTN 069/ACTG A5305." PLoS ONE. 2018;13(12):e0206577.
Kassaye SG, Grossman Z, Balamane M, et al. "Transmitted HIV Drug Resistance Is High and Longstanding in Metropolitan Washington, DC." Clin. Infect. Dis.. 2016.
Katsounas A, Frank AC, Lempicki RA, Polis MA, Asmuth DM, Kottilil S. "Differential Specificity of Interferon-alpha Inducible Gene Expression in Association with Human Immunodeficiency Virus and Hepatitis C Virus Levels and Declines in vivo." J AIDS Clin Res. 2015;6(1).
Keane NM, Roberts SG, Almeida C-AM, et al. "High-avidity, high-IFNγ-producing CD8 T-cell responses following immune selection during HIV-1 infection." Immunol. Cell Biol.. 2012;90(2):224-34.
Kearney MF, Spindler J, Wiegand A, et al. "Lower pre-ART intra-participant HIV-1 pol diversity may not be associated with virologic failure in adults." PLoS ONE. 2018;13(1):e0190438.
Kearney MF, Wiegand A, Shao W, et al. "Origin of Rebound Plasma HIV Includes Cells with Identical Proviruses That Are Transcriptionally Active before Stopping of Antiretroviral Therapy." J. Virol.. 2016;90(3):1369-76.
Keil K, Hochreitter J, DiFrancesco R, et al. "Integration of atazanavir into an existing liquid chromatography UV method for protease inhibitors: validation and application." Ther Drug Monit. 2007;29(1):103-9.
Kelesidis T, Kendall MA, Yang OO, Hodis HN, Currier JS. "Biomarkers of microbial translocation and macrophage activation: association with progression of subclinical atherosclerosis in HIV-1 infection." J. Infect. Dis.. 2012;206(10):1558-67.
Kelesidis T, Tran TTien T, Brown TT, et al. "Changes in plasma levels of oxidized lipoproteins and lipoprotein subfractions with atazanavir-, raltegravir-, darunavir-based initial antiviral therapy and associations with common carotid artery intima-media thickness: ACTG 5260s." Antivir. Ther. (Lond.). 2016.
Kelesidis T, Kendall MA, Danoff A, Aberg JA, Currier JS, Schmidt AMarie. "Soluble levels of receptor for advanced glycation endproducts and dysfunctional high-density lipoprotein in persons infected with human immunodeficiency virus: ACTG NWCS332." Medicine (Baltimore). 2018;97(22):e10955.
Kelesidis T, Tran TTien T, Stein JH, et al. "Changes in Inflammation and Immune Activation With Atazanavir-, Raltegravir-, Darunavir-Based Initial Antiviral Therapy: ACTG 5260s." Clin. Infect. Dis.. 2015;61(4):651-60.
Kelesidis T, Moser CB, Johnston E, et al. "Brief Report: Changes in Plasma RANKL-Osteoprotegerin in a Prospective, Randomized Clinical Trial of Initial Antiviral Therapy: A5260s." J. Acquir. Immune Defic. Syndr.. 2018;78(3):362-366.
Kelesidis T, Moser C, Stein JH, et al. "Changes in Markers of T-Cell Senescence and Exhaustion With Atazanavir-, Raltegravir-, and Darunavir-Based Initial Antiviral Therapy: ACTG 5260s." J. Infect. Dis.. 2016.
Kelesidis T, Kendall MA, Yang OO, Hodis H, Currier JS. "Perturbations of circulating levels of RANKL-osteoprotegerin axis in relation to lipids and progression of atherosclerosis in HIV-infected and -uninfected adults: ACTG NWCS 332/A5078 Study." AIDS Res. Hum. Retroviruses. 2013;29(6):938-48.
Kelesidis T, Yang OO, Kendall MA, Hodis HN, Currier JS. "Dysfunctional HDL and progression of atherosclerosis in HIV-1-infected and -uninfected adults." Lipids Health Dis. 2013;12:23.
Kelesidis T, Jackson N, McComsey GA, et al. "Oxidized lipoproteins are associated with markers of inflammation and immune activation in HIV-1 infection." AIDS. 2016;30(17):2625-2633.
Kelly SG, Wu K, Tassiopoulos K, Erlandson KM, Koletar SL, Palella FJ. "Frailty is an independent risk factor for mortality, cardiovascular disease, bone disease and diabetes among aging adults with HIV." Clin. Infect. Dis.. 2018.
Kemmer N, Hua L, Andersen JW, Chung RT, Butt AA, Sherman KE. "Health-related quality of life in subjects with HCV/HIV coinfection: results from ACTG 5178 study." J. Viral Hepat.. 2012;19(11):792-800.

Pages